累积甲氨蝶呤剂量与中重度银屑病患者肝纤维化无关
这项横断面研究纳入204例有中重度斑块状银屑病病史的成人,用瞬时弹性成像评估肝纤维化。结果显示累积甲氨蝶呤剂量与肝硬度值无关联,而BMI≥28、代谢综合征和糖尿病是肝纤维化的更好预测因素。
要点
- 累积甲氨蝶呤剂量与肝纤维化无显著关联。
- BMI≥28、代谢综合征和糖尿病是肝纤维化的更强预测因素。
- 银屑病患者中显著肝纤维化患病率较高。
核心结论
- 累积甲氨蝶呤剂量与肝纤维化无关联。
- BMI≥28、代谢综合征和糖尿病与更高肝硬度值相关,且比FIB-4评分更好地预测肝纤维化。
研究设计与样本
- 横断面研究,招募于2020年6月至2021年3月。
- 共240例有中重度慢性斑块状银屑病病史的成人被招募,204例具有有效肝硬度测量值的参与者纳入分析。
主要发现
- 肝纤维化患病率按LSM≥7 kPa、≥7.9 kPa和≥9.5 kPa分别为36%、25%和17%。
- 累积甲氨蝶呤剂量与连续LSM值无关联(非标准化系数0.16,95%CI -0.49至0.82,P=0.626)。
- 累积甲氨蝶呤剂量与分类LSM cutoff值无关联:≥7 kPa未调整OR 1.06(95%CI 0.97-1.15,P=0.192);≥7.9 kPa未调整OR 1.03(95%CI 0.94-1.12,P=0.577);≥9.5 kPa未调整OR 1.01(95%CI 0.91-1.12,P=0.843)。
- 与更高LSM值相关的风险因素包括BMI(P≤0.001)、腰围(P≤0.001)、代谢综合征(P≤0.001)、AUDIT评分(P=0.020)和FIB-4评分(P=0.03)。
关键数值与推荐
- 肝纤维化评估采用瞬时弹性成像,LSM阈值:≥7 kPa为轻度或更差,≥7.9 kPa为中度或更差,≥9.5 kPa为晚期。
- 累积甲氨蝶呤剂量中位数2.16(IQR 0.93-5.2)。
- BMI≥28、糖尿病和代谢综合征被证明比FIB-4评分更好地预测肝纤维化。
临床怎么用
- 对于有中重度银屑病病史的患者,应关注BMI≥28、代谢综合征和糖尿病等肝纤维化风险因素,以识别需要更详细肝脏健康评估的患者。
- 累积甲氨蝶呤剂量不应作为肝纤维化的主要风险因素考虑。
局限性
- 横断面设计无法确定因果关系。
- 样本来自单一研究,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are established risk factors for liver fibrosis (LF), but data on the impact of methotrexate on LF in patients with psoriasis are lacking. OBJECTIVES: This cross-sectional study aimed to determine the prevalence of LF in patients with psoriasis and to evaluate the relationship between LF, cumulative methotrexate dose and other LF risk factors. METHODS: Adults with a history of moderate-to-severe chronic plaque psoriasis were recruited between June 2020 and March 2021. Patients underwent transient elastography to evaluate LF. Three values for liver stiffness measurement (LSM) were assessed, indicating mild or worse LF (≥ 7 kPa), moderate or worse LF (≥ 7.9 kPa) and advanced LF (≥ 9.5kPa). Cumulative methotrexate dose and other potential risk factors for LF were assessed. RESULTS: Overall, 240 patients were recruited and 204 participants with valid LSM values were included in the analysis [median age 48 years [interquartile range (IQR) 37-57]; 51% female sex; 56% body mass index (BMI) ≥ 30 (kg m-2) and a median Alcohol Use Disorders Identification Test (AUDIT) score of 4 (IQR 1-7, 23% score ≥ 8)]. In total, 91% had received methotrexate [median duration 36 months (IQR 14-78)]. Prevalence of LF was 36%, 25% and 17% using LSM ≥ 7 kPa, ≥ 7.9 kPa and ≥ 9.5 kPa, respectively. There was no association between cumulative methotrexate dose [median 2.16 (IQR 0.93-5.2)] and continuous LSM values [unstandardized coefficient 0.16, 95% confidence interval (CI) -0.49 to 0.82, P = 0.626] or using the categorical LSM cutoff values: ≥ 7 kPa [unadjusted odds ratio 1.06 (95% CI 0.97-1.15), P = 0.192], ≥ 7.9 kPa [unadjusted odds ratio 1.03 (95% CI 0.94-1.12), P = 0.577] and ≥ 9.5 kPa (unadjusted odds ratio 1.01, 95% CI 0.91-1.12; P = 0.843). The following risk factors were associated with higher LSM values: BMI (P ≤ 0.001), waist circumference (P ≤ 0.001), metabolic syndrome (P ≤ 0.001), AUDIT score (P = 0.020) and FIB-4 score (P = 0.03). BMI ≥ 28, diabetes and metabolic syndrome were shown to be better predictors of LF compared with FIB-4 score. CONCLUSIONS: This study confirms a high prevalence of significant LF in patients with psoriasis. Cumulative methotrexate dose was not associated with LF. Patients with BMI ≥ 28, metabolic syndrome and diabetes are at higher risk for LF. These risk factors may help to identify when a more detailed liver health assessment is needed. Psoriasis is a common inflammatory skin disease affecting 3% of the UK population. People with psoriasis appear to have higher rates of liver fibrosis (scarring in the liver from injury or inflammation) compared with people without psoriasis. There are several risk factors for increasing chances of developing liver fibrosis, including obesity, alcohol and diabetes; however, there have been some concerns that methotrexate (a medicine used to treat psoriasis) could also contribute to liver fibrosis. The majority of people needing systemic therapy (such as oral medicines) will try methotrexate first as per National Institute for Health and Care Excellence (NICE) guidance. In this study carried out in the UK, we aimed to look at the relationship between the cumulative dose (total over time) of methotrexate and liver fibrosis and the relationship between other risk factors and liver fibrosis (e.g. body mass index (BMI) (a measure that uses your height and weight to work out whether your weight is healthy), diabetes, alcohol intake and metabolic syndrome (a combination of diabetes, high blood pressure and obesity)). Liver fibrosis was measured using transient elastography, which is a non-invasive technique similar to an ultrasound. We also aimed to find out whether the clinical risk factors for liver fibrosis and a simple test called a ‘FIB-4 score’ (measured using blood test values and age) can predict a person’s chance of developing liver fibrosis, in order to determine which people will benefit most from transient elastography. From our results, we were able to confirm that liver scarring is prevalent in our patients with psoriasis. We did not find an association between cumulative methotrexate and liver scarring. However, BMI, diabetes, metabolic syndrome and FIB-4 score were associated with liver scarring. We found that BMI ≥ 28, metabolic syndrome and diabetes can be used to identify patients who require a liver health assessment. Overall, the study findings suggest that cumulative methotrexate dose is not associated with liver fibrosis in people with a history of moderate-to-severe psoriasis.
引用
- Babakinejad P, Lapsley R, Forster L, et al. Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis. Br J Dermatol. 2024. PMID: 38366967. doi:10.1093/bjd/ljae069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。